Trials / Completed
CompletedNCT00169520
SB-715992 In Combination With Docetaxel In Patients With Solid Tumors
A Phase I, Open-Label Study of SB-715992 in Combination With Docetaxel in Patients With Advanced Solid Tumors.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the dose regimen of SB-715992 in combination with docetaxel in patients with solid tumors. SB-715992 and docetaxel were dosed by 1-hour intravenous infusion every 3 weeks (on the same day). A patient may continue to receive treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of both drugs in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment with SB-715992. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | docetaxel | |
| DRUG | SB-715992 |
Timeline
- Start date
- 2004-06-01
- First posted
- 2005-09-15
- Last updated
- 2008-10-16
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00169520. Inclusion in this directory is not an endorsement.